# DESTINY-Breast08 (NCT04556773)

> A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

No report yet. It can be ordered.

- Drugs tested: trastuzumab deruxtecan plus capecitabine; trastuzumab deruxtecan plus durvalumab plus paclitaxel; trastuzumab deruxtecan plus capivasertib
- Indication: HER2-low metastatic breast cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04556773
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Metastatic Breast Cancer
- Interventions: Trastuzumab deruxtecan; Durvalumab; Paclitaxel; Capivasertib; Anastrozole; Fulvestrant; Capecitabine
- Enrollment: 138
- Primary outcome: Occurrence of adverse events (AEs)- Part 1
- Primary outcome: Occurrence of serious adverse events (SAEs)- Part 1
- Primary outcome: Occurrence of adverse events (AEs)- Part 2
- Primary outcome: Occurrence of serious adverse events (SAEs)- Part 2

## Indexed commentary on DESTINY-Breast08 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 10
- X threads: 9
- Podcasts: 4
- Bluesky threads: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=destiny-breast08-nct04556773

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04556773", "email": "<work email>"}; the inbox owner confirms by the emailed link.